The Liver Meeting 2019-Ursodiol: 20 Years of Experience: Where Do We Stand?

Ursodiol: 20 Years of Experience: Where Do We Stand?

Video Transcription

Video Summary

The speaker discusses their 30 years of experience working on erythrodeoxycholic acid for PBC, highlighting its therapeutic use for liver disease. Initial studies in the late '80s showed promising results in improving gallstones and liver biochemistries. Subsequent studies supported the FDA approval of the drug in 1998. Various trials demonstrated the drug's efficacy in improving survival and reducing varices risk. The importance of patient selection, dosages, and combination therapies like abetacolic acid are also discussed. The session addresses challenges in defining endpoints for clinical trials in PBC and emphasizes the need for ongoing research to understand the mechanisms of bile acid signaling and pathophysiology in liver diseases like PSC. The discussion touches upon the role of bile acid pools, liver inflammation, and future directions for therapeutic interventions.

Asset Caption

Presenter: Keith D. Lindor

Keywords

erythrodeoxycholic acid

PBC

liver disease

gallstones

FDA approval

clinical trials

bile acid signaling